What Are the Long-term Outcomes of Mortality, Quality of Life, and Hip Function after Prosthetic Joint Infection of the Hip? A 10-year Follow-up from Sweden
- PMID: 34061486
- PMCID: PMC8445574
- DOI: 10.1097/CORR.0000000000001838
What Are the Long-term Outcomes of Mortality, Quality of Life, and Hip Function after Prosthetic Joint Infection of the Hip? A 10-year Follow-up from Sweden
Abstract
Background: Prosthetic joint infection (PJI) is a complication after arthroplasty that negatively affects patient health. However, prior reports have not addressed the long-term consequences of hip PJI in terms of patient mortality, quality of life, and hip function.
Questions/purposes: At a minimum of 10 years after PJI in patients undergoing primary THA, in the context of several large, national databases in Sweden, we asked: (1) Is mortality increased for patients with PJI after THA compared with patients with a noninfected THA? (2) Does PJI of the hip have a negative influence on quality of life as measured by the Euro-QoL-5D-5L (EQ-5D-5L), ambulatory aids, residential status, and hip function as measured by the Oxford Hip Score (OHS)? (3) Which factors are associated with poor patient-reported outcome measures (PROMs) for patients with PJI after primary THA?
Methods: This study included 442 patients with a PJI after primary THA, from a previously published national study, including all patients with a THA performed from 2005 to 2008 in Sweden (n = 45,570) recruited from the Swedish Hip Arthroplasty Registry (SHAR). Possible deep PJIs were identified in the Swedish Dispensed Drug Registry and verified by review of medical records. Mortality in patients with PJI was compared with the remaining cohort of 45,128 patients undergoing primary THA who did not have PJI. Mortality data were retrieved from the SHAR, which in turn is updated daily from the population registry. A subgroup analysis of patients who underwent primary THA in 2008 was performed to adjust for the effect of comorbidities on mortality, as American Society of Anesthesiologists (ASA) scores became available in the SHAR at that time. For the PROM analysis, we identified three controls matched by age, gender, indication for surgery, and year of operation to each living PJI patient. A questionnaire including EQ-5D-5L, ambulatory aids, residential status, and OHS was collected from patients with PJI and controls at a mean of 11 years from the primary procedure. Apart from age and gender, we analyzed reoperation data (such as number of reoperations and surgical approach) and final prosthesis in situ to explore possible factors associated with poor PROM results.
Results: After controlling for differences in sex, age, and indication for surgery, we found the all-cause 10-year mortality higher for patients with PJI (45%) compared with patients undergoing THA without PJI (29%) (odds ratio 1.4 [95% CI 1.2 to 1.6]; p < 0.001). The questionnaire, with a minimum of 10 years of follow-up, revealed a lower EQ-5D-5L index score (0.83 versus 0.94, -0.13 [95% CI -0.18 to -0.08; p < 0.001]), greater proportion of assisted living (21% versus 12%, OR 2.0 [95% CI 1.2 to 3.3]; p = 0.01), greater need of ambulatory aids (65% versus 42%, OR 3.1 [95% 2.1 to 4.8]; p < 0.001), and a lower OHS score (36 versus 44, -5.9 [-7.7 to -4.0]; p < 0.001) for patients with PJI than for matched controls. Factors associated with lower OHS score for patients with PJI were three or more reoperations (-8.0 [95% CI -13.0 to -3.2]; p = 0.01) and a direct lateral approach used at revision surgery compared with a posterior approach (-4.3 [95% CI -7.7 to -0.9]; p = 0.01).
Conclusion: In this study, we found that PJI after THA has a negative impact on mortality, long-term health-related quality of life, and hip function. Furthermore, the subgroup analysis showed that modifiable factors such as the number of reoperations and surgical approach are associated with poorer hip function. This emphasizes the importance of prompt, proper initial treatment to reduce repeated surgery to minimize the negative long-term effects of hip PJI.
Level of evidence: Level III, therapeutic study.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Association of Bone and Joint Surgeons.
Conflict of interest statement
Each author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request.
Figures



Comment in
-
CORR Insights®: What Are the Long-term Outcomes of Mortality, Quality of Life, and Hip Function after Prosthetic Joint Infection of the Hip? A 10-year Follow-up from Sweden.Clin Orthop Relat Res. 2021 Oct 1;479(10):2214-2215. doi: 10.1097/CORR.0000000000001965. Clin Orthop Relat Res. 2021. PMID: 34477573 Free PMC article. No abstract available.
Similar articles
-
Increased Mortality After Prosthetic Joint Infection in Primary THA.Clin Orthop Relat Res. 2017 Nov;475(11):2623-2631. doi: 10.1007/s11999-017-5289-6. Epub 2017 Feb 24. Clin Orthop Relat Res. 2017. PMID: 28236084 Free PMC article.
-
How do Patient-reported Outcome Scores in International Hip and Knee Arthroplasty Registries Compare?Clin Orthop Relat Res. 2022 Oct 1;480(10):1884-1896. doi: 10.1097/CORR.0000000000002306. Epub 2022 Jul 8. Clin Orthop Relat Res. 2022. PMID: 35901444 Free PMC article.
-
Poor Knee-specific and Generic Patient-reported Outcome Measure Scores at 6 Months Are Associated With Early Revision Knee Arthroplasty: A Study From the Australian Orthopaedic Association National Joint Replacement Registry.Clin Orthop Relat Res. 2022 Oct 1;480(10):1899-1909. doi: 10.1097/CORR.0000000000002301. Epub 2022 Jun 30. Clin Orthop Relat Res. 2022. PMID: 35901436 Free PMC article.
-
Outcomes of different bearings in total hip arthroplasty - implant survival, revision causes, and patient-reported outcome.Dan Med J. 2017 Mar;64(3):B5350. Dan Med J. 2017. PMID: 28260601 Review.
-
Discordance Abounds in Minimum Clinically Important Differences in THA: A Systematic Review.Clin Orthop Relat Res. 2023 Apr 1;481(4):702-714. doi: 10.1097/CORR.0000000000002434. Epub 2022 Oct 19. Clin Orthop Relat Res. 2023. PMID: 36398323 Free PMC article.
Cited by
-
Direct Costs Vary by Outcome in Two-Stage Revision Arthroplasty for the Treatment of Hip Periprosthetic Joint Infection.Arthroplast Today. 2022 Nov 28;19:101061. doi: 10.1016/j.artd.2022.10.011. eCollection 2023 Feb. Arthroplast Today. 2022. PMID: 36465692 Free PMC article.
-
In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement.Antibiotics (Basel). 2023 Sep 13;12(9):1445. doi: 10.3390/antibiotics12091445. Antibiotics (Basel). 2023. PMID: 37760741 Free PMC article.
-
Mortality, patient-reported outcome measures, and the health economic burden of prosthetic joint infection.EFORT Open Rev. 2023 Sep 1;8(9):690-697. doi: 10.1530/EOR-23-0078. EFORT Open Rev. 2023. PMID: 37655835 Free PMC article. Review.
-
Long-Term Outcomes of Staged Revision Surgery for Chronic Periprosthetic Joint Infection of Total Hip Arthroplasty.J Clin Med. 2021 Dec 27;11(1):122. doi: 10.3390/jcm11010122. J Clin Med. 2021. PMID: 35011863 Free PMC article.
-
Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.BMC Infect Dis. 2023 Oct 19;23(1):706. doi: 10.1186/s12879-023-08709-8. BMC Infect Dis. 2023. PMID: 37858087 Free PMC article.
References
-
- Aboltins CA, Berdal JE, Casas F, et al. Hip and knee section, prevention, antimicrobials (systemic): proceedings of international consensus on orthopedic infections. J Arthroplasty. 2019;34:S279-S288. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials